Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 24:13:1124591.
doi: 10.3389/fcimb.2023.1124591. eCollection 2023.

Interactions between microbiota and cervical epithelial, immune, and mucus barrier

Mengting Dong  1   2 , Yalan Dong  1   2 , Junyi Bai  1   2 , Huanrong Li  1   2 , Xiaotong Ma  1   2 , Bijun Li  1   2 , Chen Wang  1   2 , Huiyang Li  1   2 , Wenhui Qi  1   2 , Yingmei Wang  1   2 , Aiping Fan  1   2 , Cha Han  1   2 , Fengxia Xue  1   2
Affiliations
Review

Interactions between microbiota and cervical epithelial, immune, and mucus barrier

Mengting Dong et al. Front Cell Infect Microbiol. .

Abstract

The female reproductive tract harbours hundreds of bacterial species and produces numerous metabolites. The uterine cervix is located between the upper and lower parts of the female genital tract. It allows sperm and birth passage and hinders the upward movement of microorganisms into a relatively sterile uterus. It is also the predicted site for sexually transmitted infection (STI), such as Chlamydia, human papilloma virus (HPV), and human immunodeficiency virus (HIV). The healthy cervicovaginal microbiota maintains cervical epithelial barrier integrity and modulates the mucosal immune system. Perturbations of the microbiota composition accompany changes in microbial metabolites that induce local inflammation, damage the cervical epithelial and immune barrier, and increase susceptibility to STI infection and relative disease progression. This review examined the intimate interactions between the cervicovaginal microbiota, relative metabolites, and the cervical epithelial-, immune-, and mucus barrier, and the potent effect of the host-microbiota interaction on specific STI infection. An improved understanding of cervicovaginal microbiota regulation on cervical microenvironment homeostasis might promote advances in diagnostic and therapeutic approaches for various STI diseases.

Keywords: cervicovaginal microbiota; chlamydia trachomatis; epithelial; human immunodeficiency virus; human papilloma virus; immune; mucus; uterine cervix.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
A healthy Lactobacillus dominant microbiota and the acidic environment formed by the associated metabolites especially lactic acid maintain cervical epithelial barrier integrity, stabilise the mucosal immune system. In contrast, microbiota dysbiosis and its accompanying changes in microbial metabolites can 1) damage mucus layer; 2) imbalance immune system: promote immune cells differentiate towards proinflammatory type and induce pro- and inflammatory cytokines secretion; 3) disrupt cervical epithelial barrier: induce inflammation reaction, oxidative stress, miRNA alteration of cervical epithelial cell, decrease intracellular junctions, and promote cell cycle arrest, apoptosis, and necrosis. Thus, increase the epithelial permeability and disrupt barrier function.
See this image and copyright information in PMC

References

    1. Aflatoonian R., Fazeli A. (2008). Toll-like receptors in female reproductive tract and their menstrual cycle dependent expression. J. Reprod. Immunol. 77 (1), 7–13. doi: 10.1016/j.jri.2007.03.014 - DOI - PubMed
    1. Ahire J. J., Sahoo S., Kashikar M. S., Heerekar A., Lakshmi S. G., Madempudi R. S. (2021). In vitro assessment of lactobacillus crispatus UBLCp01, lactobacillus gasseri UBLG36, and lactobacillus johnsonii UBLJ01 as a potential vaginal probiotic candidate. Probiotics Antimicrob. Proteins. doi: 10.1007/s12602-021-09838-9 - DOI - PubMed
    1. Aiyar A., Quayle A. J., Buckner L. R., Sherchand S. P., Chang T. L., Zea A. H., et al. . (2014). Influence of the tryptophan-indole-IFNγ axis on human genital chlamydia trachomatis infection: role of vaginal co-infections. Front. Cell Infect. Microbiol. 4. doi: 10.3389/fcimb.2014.00072 - DOI - PMC - PubMed
    1. Alcaide M. L., Strbo N., Romero L., Jones D. L., Rodriguez V. J., Arheart K., et al. . (2016). Bacterial vaginosis is associated with loss of gamma delta T cells in the female reproductive tract in women in the Miami women interagency HIV study (WIHS): A cross sectional study. PloS One 11 (4), e0153045. doi: 10.1371/journal.pone.0153045 - DOI - PMC - PubMed
    1. Aldunate M., Tyssen D., Johnson A., Zakir T., Sonza S., Moench T., et al. . (2013). Vaginal concentrations of lactic acid potently inactivate HIV. J. Antimicrob. Chemother. 68 (9), 2015–2025. doi: 10.1093/jac/dkt156 - DOI - PMC - PubMed

Publication types